Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Where did you read 15 days ??
The filing said:
GW Pharma 8.15.2010 quote:
on youtube
Dennis Peron raided by SF cops??
Cannabis Culture
Here is the ballot measure for Oregon's dispensary measure.
at ballotpedia
Hoping to submit a voter's pamphlet argument in support -- need 500 signatures by EOM.
Last year, on Aug. 14th CBIS filed a "notice of extension" for filing the quarterly. I am hoping the quarterly is filed by Friday or Monday.
Today's volume was pumped by Stock up Stocks
Supposedly a free promotion.
I like this quote:
Kerlikowske is not pro legalization. He has been quoted several times as say that legalization is not in his vocabulary....after which several legalization groups sent him some new dictionaries.
I have yet to find a consistent free source for buy/sell data that is reliable.
Ihub's numbers are always off. Even the bid/ask seem off most of the time.
OTCBB numbers reflect a buy when price goes up, and sell when price goes down, and neutral when it price is same as previous order. The problem with OTCBB is the data only goes back for like 20 or so orders and not the whole day.
I guess you get what you pay for. lol
Seems that buyers are "sic" this morning. LOL
Thanks for the "BS"
20100804|CBIS|63744|376392
Low Volume
Low Short
Lets see some news tomorrow !!
Yes, there are many states(14) that have decriminalized/legalized, in some fashion, medical marijuana. Many other states are considering adding some form of decriminalization/legalization for medical use.
In Oregon, we have had medical marijuana for over 10 years. In November, voters may add dispensaries in addition to the MMJ program.
It won't be long until the federal government capitulates.
Bull shoot
AUTO was sure active today (Wednesday).
My broker is Merrill Lynch and my trades go through AUTO. Even though I have a sell price on all my shares, I could have sworn that AUTO made a trade (short) reflecting my share structure.
CBIS will probably file its quarterly report in the next 5 days, because CBIS will get into trouble with FINRA for filling late. Most longs will remember the "E" last couple times. FINRA gets mad at the 3rd "E".
Opening price could be .075, with good volume, and less sell pressure, CBIS could explode today !!!
I've been going on the assumption the sell pressure was due to s-8's and MM shorting.
Go CBIS !!
Never been to Arizona, heard there are rednecks there.
While immigration laws are in the realm of federal jurisdiction, the 9th Amendment and other parts of the Constitution gives the police powers to States. States can determine what punishments they put on Cannabis.
Federal law will eventually change. Baby steps, maybe !
The VA announce does not change federal law, only allows veterans to not be punished for following state law.
Thanks for the post on Oregon rescheduling. Hopefully, the story doesn't end there. It is under appeal because it should have been scheduled lower, like about V.
I submitted testimony on the rescheduling, that it should have been removed from all scheduling.
20100727|CBIS|902311|1961966|
This Stock is buzzing at wisepennystocks
Looking for a buying frenzy tomorrow morning. Hoping to see .124 by noon, GLTA
News Release:
www.tradingmarkets.com/news/press-release/cbis_cannabis-science-comments-on-ny-times-article-regarding-major-support-from-veterans-affairs-for-medi-1065969.html[tag]Cannabis Science Comments on NY Times Article Regarding Major Support From Veterans Affairs for Medical Marijuana;
Cannabis Science[/tag]
Posted on: Mon, 26 Jul 2010 16:15:16 EDT
COLORADO SPRINGS, Colo., Jul 26, 2010 (GlobeNewswire via COMTEX) --
Cannabis Science, Inc. (OTCBB: CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is hailing the Veterans Affairs' new policies on medical marijuana for disabled vets as a triumph of science and compassion.
On Friday The New York Times reported, "Under department rules, veterans can be denied pain medications if they are found to be using illegal drugs. Until now, the department had no written exception for medical marijuana. This has led many patients to distrust their doctors, veterans say. With doctors and patients pressing the veterans department for formal guidance, agency officials began drafting a policy last fall."
According to a letter issued by the U.S. Department of Veteran Affairs, Under Secretary of Health Robert Petzel, M.D. "a patient's use of medical cannabis is not sufficient cause to deny him or her access to prescribed pain medications in a Veterans Affairs facility" -- however, these new rules apply only in states with medical marijuana laws.
The letter to Michael Krawitz, administrator for the group Veterans for Medical Marijuana Access, states: "If a Veteran obtains and uses medical marijuana in a manner consistent with state law, testing positive for marijuana would not preclude the Veteran from receiving opioids for pain management in a Department of Veterans Affairs (VA) facility. ... Standard pain management agreements should draw a clear distinction between the use of illegal drugs, and legal medical marijuana."
Krawitz had contacted the agency after hearing several complaints from veterans who had been denied treatment at VA facilities because of their state-authorized use of medical cannabis.
Cannabis Science President and CEO, Dr. Robert Melamede, PhD, commented, "We see this announcement as a validation of our strategy of focusing on helping disabled vets suffering from PTSD, chronic pain, and other problems. Nonetheless, it is shocking to think that disabled veterans in states without medical marijuana laws can still be denied 'access to prescribed pain medications in a Veterans Affairs facility.' That is tantamount to torture and good medicine and basic human decency do not change from state to state."
Richard Cowan, Cannabis Science CFO, added, "We are still sacrificing real war heroes to satisfy the blood lust of the cowardly drug warriors. Those who fought for our freedom should not have to move to another state to get life saving medicine."
On March 31 Cannabis Science issued a press release calling for public support for vets after the New York Times reported that VA Doctors are prohibited from "recommending" cannabis for Post Traumatic Stress Disorder (PTSD). Also, Cannabis Science has previously reported that Dr. Mitch Earleywine, PhD. of the State University of New York (Albany) has surveyed over 1,300 veterans and others who find cannabis very helpful with PTSD.
On May 20th, Cannabis Science issued another press release reporting that a widely-prescribed medication has been linked to both suicides and sudden death among veterans suffering from PTSD.
According to an article by Martha Rosenberg originally published on Alternet.org and published in March on NewsBlaze.com reported that at least 87 military men have died in the past six years while prescribed Seroquel and similar drugs. http://newsblaze.com/story/20100324080950rose.nb/topstory.html
Rosenberg reported, "Death certificates and other records collected by veteran family members suggest more than 100 similar deaths among Iraq and Afghanistan combat vets and other military personnel, many on PTSD cocktails with Seroquel and other antipsychotics, antidepressants, mood stabilizers, sleep inducers and pain and seizure medications."
Dr. Melamede commented, "Of course, after more than 5,000 years of use, cannabis has not been shown to have caused a single death, and it is now widely -- but illegally -- used by veterans and others with PTSD as we have reported. It is shameful that those who deserve the best treatment available are being denied access to cannabis while they are given a cocktail of powerful drugs that seems to be killing them."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Cannabis Science, Inc.
CONTACT: Cannabis Science Inc.
Investor Relations
Mark J. Friedman
1.877.431.CBIS (2247)
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
Yeah, I think the shorts are covering yesterday's position, judging from the two 50,000 lots at the ask (.071)
That's a good sign, eh?
Good question.
I am not sure. I know that one year ago K&D owned 23% of the share structure. I kind of remember something about a settlement with K&D prior to the Kubby suit, but am unable to find more info.
.07 may be the bottom on this, based upon the following statements in the 10-Q filing of May 21, 2010.
I think it is safe to say that the MMs sold the opening 100,000 lot from shares they didn't have(shorted) at .09.
Jeesh, someone got screwed on the opening bid today.
100,000 share order placed before the opening, to be filled at opening bell, in the hopes of filling at the previous close was @ .07. .... the MMs seen this coming and purchased shares before the opening bell to bring the opening price up to .09 and then made the sale. ... it cost the buyer an extra $2,000 bucks.
The lesson to be learned here is that if you are going to make a large opening bid, only do it seconds before the bell to avoid MM manipulation of the opening price. WOW, a hard lesson to learn for someone. OUCH !!!! I think we can all learn from this mistake !
Was just thinking it was about time for a pr. ... its been a while.
Was hoping the company was wanting to protect PPS, was hoping maybe one of the Board adviser's would relay some expertise on CBIS's ideas.
Tuesday would be a nice day to recover PPS.
Maybe some news without the selling pressure ??
Looks like the shorts were able to cover on the low.
And this from shortablestocks
Symbol: CBIS
Availability: 8'000
Exchanges: PINK, NITE, ARCAEDGE, IBSX, OTCBB
The selling continues .... looks like the last hour or so belonged to MMs.
I'm looking for some news in the morning !!!
Sorry, this is old news, ... really old news that has been settled.
Marijuana is "anti-aging" and "curative" drug, speakers say at Kalamazoo seminar
Published: Saturday, July 10, 2010, 10:00 PM
Chris Killian |Special to the Kalamazoo Gazette Chris Killian
KALAMAZOO —
....
....
One of the first speakers Saturday was Robert J. Melamede, president and chief executive officer of Cannabis Science Inc., associate professor at the University of Colorado at Colorado Springs and nationally recognized expert on the science of marijuana.
Melamede said that the human brain contains what’s called the endocannabinoid system, a series of receptors that are involved with a variety of physiological processes ranging from memory to mood to appetite, among several others.
“It’s like a thermostat that regulates the body,” he said.
And it’s also a system that can be heightened by the use of marijuana, he said, which he called “an essential nutrient” that provides anti-aging properties by “smoothing out” free radicals in the body, which contribute to a host of diseases.
Apart from the therapeutic use of marijuana by those like Falco, or others with a wasting disease, cancer or AIDS, Melamede touted the use of marijuana — “a puff or two a day” — by healthy people as a way to live a longer, more healthful life.
Marijuana — and more specifically the cannabinoids in it — staves off inflammation, delays the onset of auto-immune diseases, inhibits the formation of Alzheimer’s disease and can help treat or even cure some types of cancer, he said.
“Cannabinoids have curative or at least palliative properties,” Melamede said. “It should be the first line of treatment.”
But even though Michigan and several other states have medical marijuana laws that enable those who qualify to possess and use the drug to treat a host of illnesses, the drug is still illegal.
And for Melamede, that’s not just a problem, it’s negligent considering the myriad positive properties of the drug, he said.
“The fact that we have an anti-aging drug that kills cancer is proof of their (the government’s) incompetence” in terms of marijuana still being illegal, he said.
This weekend’s seminar is the first for 420 University, said Michelle Martin, vice president for development for the university. It is planning seminars in Chicago and cities in Wisconsin in coming months, spreading its message of the benefits of marijuana.
And the group believes it can make an impact.
“It gives people more confidence that marijuana is useful as they speak to people who have been in the industry for a long time,” Martin said. “We’re starting to build a platform for a discussion of the issues.”
Harvard economist Jeffrey Miron estimates that, nationally, the medical marijuana market is bringing in roughly $14 billion a year. Those who benefit range from center owners to real-estate agents, from attorneys to insurance salesmen.
Little pharma
by Edie Adelstein Colorado Springs Independent
Like most businesses in the medical marijuana industry, Cannabis Science is out to change the face of medicine. Unlike your standard center, however, this company is doing it in the lab.
No one said it would be easy. "Why does law enforcement and why do our politicians and policy makers, why do they feel it's OK to put people on addictive narcotics rather than a health-giving herb that's actually nonaddictive and it's an anti-aging drug?" says an exasperated Dr. Robert Melamede.
"Why would anybody in their right mind outlaw an anti-aging drug with anti-cancer properties, and that's found in mother's milk? That's the kind of stuff we've been dealing with for decades."
Melamede, a microbiology professor at the University of Colorado at Colorado Springs, feels science is the answer, so he helped create Cannabis Science, a biotech company that develops pharmaceutical cannabis products. The enterprise grew out of the shell of a previous company a year and a half ago, when Melamede took over as president and CEO.
Also at the helm is Chris Stubbs, 27, Cannabis Science's lab director, whose job entails recruiting people for the company's current 20-member team, and helping run the labs. Like all other employees, Stubbs also researches partnerships, including last month's Montana Pain Management acquisition. He says Cannabis Science receives numerous inquiry requests for partnerships. "It's almost too hard to handle right now."
It's a revolutionary — and publicly traded — company that Colorado Springs is about to lose.
Moving out
Earlier this year, Melamede wrote several e-mails to City Council introducing himself, and his company, and says he never heard back. He did eventually call Councilor Sean Paige, and says the two had a pleasant conversation, but Council's overall hesitation to even talk was enough to convince Melamede and Co. that the Springs was not the most stable place for this $7 million to $10 million enterprise.
"It just made more sense to go where [city MMJ] regulations seem to be a bit more solidly in place and established," Melamede says, though he acknowledges that the late-May ordinance passed by Council is a step in the right direction.
"We don't want to be down here in limbo," adds Stubbs. "I don't want to look at temporary measures and temporary application forms and temporary anything. This is a permanent operation that needs to be in a permanent home.
"Not being able to open a direct dialogue with City Council or explain the goals that we have as a company, does not lend itself well to us putting our chips into the Colorado Springs business basket."
The benefits in Denver, where the company already has a center, include stable municipal laws, as well as a less suspicious district attorney, according to Stubbs and Melamede.
They aren't wasting time. The scientists estimate the core labs, offices and manufacturing facilities in Denver will be complete by the end of summer.
Once settled in the Denver facility, Stubbs says Cannabis Science will be able to further its research for oral and topical cannabis drugs, with the goal of achieving U.S. Food and Drug Administration approval in MMJ-friendly states. (It's already hired a regulatory group to guide it through the application for phase one FDA clinical trial work.) And it will still offer buds for smoking, edibles and beverages.
Down the road, Stubbs says, the company hopes to have an "affiliate partnership" back in the Springs, as well as in other cities on the Front Range and the Western Slope.
Med cred
Until then, our city will still benefit from Cannabis Science's research, because much of its mission involves bringing medical-grade standards and quality to the MMJ industry.
Stubbs says the industry needs more education: Even the most well-intentioned center owners and growers are selling worse than low-grade products. (Stubbs says the company will have a cannabis testing operation available to growers and MMJ centers.)
"I cannot tell you how many dispensaries I've been in, in the state of Colorado, that have at least one jar of cannabis that has some kind of mold on it," he says.
"There's a significant need — if we're going to call this medicine — to ensure that it's not going to have any adverse effects. Because the safety level of cannabis, generally, is very high, but people with severe autoimmune deficiencies ... absolutely cannot have any infectious agents entering their body like that. Some people have trouble eating certain kinds of food, much less inhaling a bunch of mold."
On a larger scale, Stubbs says he's in the process of establishing MMJ manufacturing practices, quality controls and other standard operating procedures. He's borrowing regulations from the FDA for pharmaceutical companies, nutraceutical companies and other sectors. "My job is to just tighten everybody up," he says.
Stubbs hopes to share these procedures with an ever-growing group of physicians who are curious about the cannabis their patients are raving about. Cannabis Science wants to facilitate MMJ exploration and acceptance.
"Even if it is decriminalized and fully legalized — let's say we can all carry around as much as we want — there's still going to be a need for Cannabis Science and FDA products," Stubbs says. "You don't see people growing their own Tylenol."
Another marijuana stock this morning has this on pinksheets:
unsolicited warning
I get it.
I do not follow the logic of that statement.